Amgen's [BiTE]® technology is a targeted immuno-oncology platform designed to engage patients’ own T cells to any tumor-specific antigen to fight cancers. To learn more about the BiTE® platform’s versatility and potential for patients with difficult-to-treat cancers like multiple myeloma, acute lymphoblastic leukemia, and prostate cancer, Dr. Matt Birnholz is joined by Dr. Ajai Chari.

USA-OCF-80679

The age-related decline in immunity is a dominant driver of shingles,1-3 an issue of special concern to older patients. Dr. Jeffrey Stoddard, US Medical Affairs Lead of Zoster Vaccines at GSK, discusses how SHINGRIX addresses this potentially serious health issue. You’ll hear about the vaccine’s high efficacy rates in patients 50 years and older,4 the results of pivotal clinical studies, CDC recommendations, and more.

References:

1. Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med. 2007;356(13):1338-1343.
2. Centers for Disease Control and Prevention. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2008;57(RR-5):1-30.
3. Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol. 2012;24(4):494-500.
4. Prescribing Information for SHINGRIX.

Dr. Jan Shepherd and Dr. Jeff Levine discuss how engaging in a patient-centered dialogue with our patients can help increase their satisfaction and the likelihood that they will use their chosen method properly and consistently.

References

1. Gavin L et al. Providing quality family planning services: Recommendations of CDC and the U.S. Office of Population Affairs. MMWR Morb Mortal Wkly Rep. 2014;63:1‒54.
2. Gavin L et al. Update: Providing Quality Family Planning Services - Recommendations from CDC and the U.S. Office of Population Affairs, 2017. MMWR Morb Mortal Wkly Rep. 2017;66:1383‒1385.
3. Wysocki S. The state of hormonal contraception today: enhancing clinician/patient communications. Am J Obstet Gynecol. 2011;205(4 suppl):S18–S20.
4. Finer LB et al. Declines in Unintended Pregnancy in the United States, 2008–2011. N Engl J Med. 2016;374:843–852.
5. Sonfield A et al. Moving forward: Family planning in the era of health reform. Guttmacher Institute; March 2014. https://www.guttmacher.org/sites/default/files/report_pdf/family-planning-and-health-reform.pdf, Accessed January 17, 2019.

US-XPL-00789 08/19

Copyright © 2019 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.

An average of 37.5 million menopausal women in the US between the ages of 45 and 64 experience symptoms such as hot flashes and joint pain, but there are other symptoms that we rarely talk about: symptoms like vaginal dryness and dyspareunia.

Featuring a patient and a panel of experts, this discussion reviews strategies that can be used to help patients feel comfortable in bringing up their struggles with menopause along with how we can help relieve women from their pain.

©2019 NP-INR-US-00214 09/19

The treatment landscape for Multiple Myeloma is continuing to rapidly evolve, which is why it’s important for healthcare professionals to stay up-to-date on all of the FDA-approved therapy options that are available, including triplets with POMALYST. Join Dr. Jeff Matous from the Colorado Blood Cancer Institute in Denver as he discusses a triplet with POMALYST® and the clinical trial that evaluated its efficacy and safety in patients with Relapsed/Refractory Multiple Myeloma.

This information is intended for US audiences only.

Dr. Matous was paid a fee by Celgene for his participation in this program.

POMALYST Indication

POMALYST® (pomalidomide) is a thalidomide analogue indicated, in combination with dexamethasone, for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.

POMALYST + dexamethasone + daratumumab Indication

POMALYST + dexamethasone + daratumumab is indicated for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.

Information about POMALYST + dexamethasone + daratumumab does not appear in the POMALYST Prescribing Information (PI). Please see ...

Please click for Full Prescribing Information.

INDICATION AND LIMITATIONS OF USE

MYDAYIS® (mixed salts of a single-entity amphetamine product) is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients ≥13 years. Patients ≤12 years experienced higher plasma exposure at the same dose and higher rates of adverse reactions, mainly insomnia and decreased appetite.

IMPORTANT SAFETY INFORMATION

• CNS stimulants, including Mydayis, other amphetamine-containing products, and methylphenidate, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.

• Contraindications
  • Known hypersensitivity to amphetamines or other ingredients of Mydayis. Angioedema and anaphylactic reactions have been reported with other amphetamines.
  • Use with monoamine oxidase inhibitors (MAOIs) or within 14 days of last MAOI dose, due to increased risk of hypertensive crisis.
• Warnings and Precautions
  • Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmia, coronary artery disease, and other serious heart problems. Sudden death, stroke and myocardial infarction have been ...

Please click for Full Prescribing Information.

INDICATION AND LIMITATIONS OF USE

MYDAYIS® (mixed salts of a single-entity amphetamine product) is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients ≥13 years. Patients ≤12 years experienced higher plasma exposure at the same dose and higher rates of adverse reactions, mainly insomnia and decreased appetite.

IMPORTANT SAFETY INFORMATION

• CNS stimulants, including Mydayis, other amphetamine-containing products, and methylphenidate, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.

• Contraindications
  • Known hypersensitivity to amphetamines or other ingredients of Mydayis. Angioedema and anaphylactic reactions have been reported with other amphetamines.
  • Use with monoamine oxidase inhibitors (MAOIs) or within 14 days of last MAOI dose, due to increased risk of hypertensive crisis.
• Warnings and Precautions
  • Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmia, coronary artery disease, and other serious heart problems. Sudden death, stroke and myocardial infarction have been ...

Please click for Full Prescribing Information.

INDICATION AND LIMITATIONS OF USE

MYDAYIS® (mixed salts of a single-entity amphetamine product) is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients ≥13 years. Patients ≤12 years experienced higher plasma exposure at the same dose and higher rates of adverse reactions, mainly insomnia and decreased appetite.

IMPORTANT SAFETY INFORMATION

• CNS stimulants, including Mydayis, other amphetamine-containing products, and methylphenidate, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.

• Contraindications
  • Known hypersensitivity to amphetamines or other ingredients of Mydayis. Angioedema and anaphylactic reactions have been reported with other amphetamines.
  • Use with monoamine oxidase inhibitors (MAOIs) or within 14 days of last MAOI dose, due to increased risk of hypertensive crisis.
• Warnings and Precautions
  • Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmia, coronary artery disease, and other serious heart problems. Sudden death, stroke and myocardial infarction have been ...

Intended for U.S. Healthcare Professionals Only.

When it comes to treating ADHD, a multidisciplinary approach involving numerous health experts can be key, but at the center of it all and with a level of familiarity born out of personal experience are the patients themselves.

Joining Dr. Matt Birnholz from Denver, Colorado is Shannon R., an adult patient who shares her experience living with ADHD and how it has affected her in multiple settings. Shannon R. is a paid consultant for Shire.

Millions of patients go to the hospital each year with symptoms like diarrhea caused by bacterial, parasitic, and viral pathogens, and these gastrointestinal infections can be particularly harmful in children. Joining Dr. Jennifer Caudle to examine how new guidelines can help direct our approach and, by extension, improve care decisions going forward is Dr. Mark Murphy.